Top

Published in:

Open Access 01-12-2020 | Stroke | Review

Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations

Authors: Keon Pearson, Fatima Rodriguez

Published in: Cardiology and Therapy | Issue 2/2020

Abstract

Lipoprotein(a) (Lp(a)) is a highly proatherogenic lipid fraction that is genetically determined and minimally responsive to lifestyle or behavior changes. Mendelian randomization studies have suggested a causal link between elevated Lp(a) and heart disease, stroke, and aortic stenosis. There is substantial inter-ethnic variation in Lp(a) levels, with persons of African descent having the highest median values. Monitoring of Lp(a) has historically been limited by lack of standardization of assays. With the advent of novel therapeutic modalities to lower Lp(a) levels including proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors and targeted antisense oligonucleotides, it is increasingly important to screen patients who have family or personal history of atherosclerotic cardiovascular disease for elevations in Lp(a). Further study is needed to establish a causal relationship between elevated Lp(a) and cardiovascular disease across diverse ethnic populations.

Chan L. Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins. J Biol Chem. 1992;267(36):25621–4.PubMed

Koschinsky: Structure, function and regulation of… - Google Scholar [Internet]. [cited 2020 Mar 24]. https://scholar.google.com/scholar_lookup?title=Structure%2C%20function%20and%20regulation%20of%20lipoprotein%28a%29&journal=Curr%20Pharm%20Design&volume=2&pages=121-121&publication_year=1996&author=Koschinsky%2CML&author=Ramharack%2CR. Accessed 24 Mar 2020.

Utermann G. The mysteries of lipoprotein(a). Science. 1989;246(4932):904–10.PubMed

Anglés-Cano E, de la Peña Díaz A, Loyau S. Inhibition of fibrinolysis by lipoprotein(a). Ann NY Acad Sci. 2001;936:261–75.PubMed

Topçiu-Shufta V, Begolli L, Kryeziu E. Lipoprotein(a) as an acute-phase reactant in patients on chronic hemodialysis. Bosn J Basic Med Sci. 2010;10(1):19–25.PubMedPubMedCentral

Lp(a): an acute-phase reactant? - ScienceDirect [Internet]. [cited 2020 Feb 18]. https://www.sciencedirect.com/science/article/pii/0009308494901643. Accessed 18 Feb 2020.

Hoover-Plow J, Hart E, Gong Y, Shchurin A, Schneeman T. A physiological function for apolipoprotein(a): a natural regulator of the inflammatory response. Exp Biol Med (Maywood). 2009;234(1):28–34.PubMed

Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med. 2011;5(5):673–94.PubMed

Tsimikas S, Willeit P, Willeit J, Santer P, Mayr M, Xu Q, et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol. 2012;60:2218–29.PubMed

10.

Sung K-C, Wild SH, Byrne CD. Lipoprotein(a), metabolic syndrome and coronary calcium score in a large occupational cohort. Nutr Metab Cardiovasc Dis. 2013;23(12):1239–46.PubMed

11.

Silaste M-L, Rantala M, Alfthan G, Aro A, Witztum JL, Kesäniemi YA, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol. 2004;24(3):498–503.PubMed

12.

Cardoso GC, Posadas C, Orvanaños OO, Peniche C, Zamora J, Aguilar R, et al. Long distance runners and body-builders exhibit elevated plasma levels of lipoprotein(a). Chem Phys Lipid. 1994;1(67–68):207–21.

13.

Holme I, Urdal P, Anderssen S, Hjermann I. Exercise-induced increase in lipoprotein(a). Atherosclerosis. 1996;122(1):97–104.PubMed

14.

Cohen LI, Hartford CG, Rogers GG. Lipoprotein(a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sports Exerc. 1996;28(2):176–9.PubMed

15.

Ponjee GAE, Janssen EME, van Wersch JWJ. Long-term physical exercise and lipoprotein(a) Levels in a previously sedentary male and female population. Ann Clin Biochem. 1995;32(2):181–5.PubMed

16.

Hubinger L, Mackinnon LT. The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males. Med Sci Sports Exerc. 1996;28(6):757–64.PubMed

17.

Hubinger L, Mackinnon LT, Lepre F. Lipoprotein(a) [Lp(a)] levels in middle-aged male runners and sedentary controls. Med Sci Sports Exerc. 1995;27(4):490–6.PubMed

18.

Mankowitz K, Seipa R, Semenkovich CF, Daugherty A, Schonfeld G. Short-term interruption of training affects both fasting and post-prandial lipoproteins. Atherosclerosis. 1992;95(2):181–9.PubMed

19.

Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89(3):975–90.PubMed

20.

Lobo RA, Notelovitz M, Bernstein L, Khan FY, Ross RK, Paul WL. Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen. Am J Obstet Gynecol. 1992;166(4):1182–90.PubMed

21.

Seip RL, Moulin P, Cocke T, Tall A, Kohrt WM, Mankowitz K, et al. Exercise training decreases plasma cholesteryl ester transfer protein. Arterioscler Thromb. 1993;13(9):1359–67.PubMed

22.

Oyelola OO, Rufai MA. Plasma lipid, lipoprotein and apolipoprotein profiles in Nigerian university athletes and non-athletes. Br J Sports Med. 1993;27(4):271–4.PubMedPubMedCentral

23.

Halle M, Berg A, von Stein T, Baumstark MW, König D, Keul J. Lipoprotein(a) in endurance athletes, power athletes, and sedentary controls. Med Sci Sports Exerc. 1996;28(8):962–6.PubMed

24.

Israel RG, Sullivan MJ, Marks RHL, Cayton RS, Chenier TC. Relationship between cardiorespiratory fitness and lipoprotein(a) in men and women. Med Sci Sports Exerc. 1994;26(4):425–31.PubMed

25.

Mackinnon LT, Hubinger LM. Effects of exercise on lipoprotein(a). Sports Med 1999. 1999;28(1):11–24.

26.

Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ [Internet]. 2018 Jul 12 [cited 2020 Apr 7];362. https://www.bmj.com/content/362/bmj.k601. Accessed 7 Apr 2020.

27.

Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38(8):904–9.PubMed

28.

Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the lipid research clinics coronary primary prevention trial. JAMA. 1994;271(13):999–1003.PubMed

29.

Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40(33):2760–70.PubMed

30.

Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG. Lipoprotein(a)-lowering by 50 mg/dl (105 nmol/l) may be needed to reduce cardiovascular disease 20% in secondary prevention. Arteriosclerosis, Thromb Vasc Biol. 2020;40(1):255–66.

31.

Gudbjartsson DF, Thorgeirsson G, Sulem P, Helgadottir A, Gylfason A, Saemundsdottir J, et al. Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982–94.PubMed

32.

Wang J, Zhang C, Han A, Gong J, Li K. Percutaneous coronary intervention results in acute increases in native and oxidized lipoprotein(a) in patients with acute coronary syndrome and stable coronary artery disease. Clin Biochem. 2010;43(13):1107–11.PubMed

33.

Konishi H, Miyauchi K, Tsuboi S, Ogita M, Naito R, Dohi T, et al. Plasma lipoprotein(a) predicts major cardiovascular events in patients with chronic kidney disease who undergo percutaneous coronary intervention. Int J Cardiol. 2016;15(205):50–3.

34.

Konishi H, Miyauchi K, Shitara J, Endo H, Wada H, Doi S, et al. Impact of lipoprotein(a) on long-term outcomes in patients with diabetes mellitus who underwent percutaneous coronary intervention. Am J Cardiol. 2016;118(12):1781–5.PubMed

35.

O’Donoghue ML, Morrow DA, Tsimikas S, Sloan S, Ren AF, Hoffman EB, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am Coll Cardiol. 2014;63(6):520–7.PubMed

36.

Langsted A, Nordestgaard BG, Kamstrup PR. Elevated lipoprotein(a) and Risk of ischemic stroke. J Am Coll Cardiol. 2019;74(1):54–66.PubMed

37.

Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301(22):2331–9.PubMed

38.

Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the Primary prevention of stroke. Stroke. 2011;42(2):517–84.PubMed

39.

Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke. Stroke. 2014;45(12):3754–832.PubMedPubMedCentral

40.

Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G. Estimating the population impact of Lp(a) lowering on the incidence of myocardial infarction and aortic stenosis—brief report. Arterioscler Thromb Vasc Biol. 2016;36(12):2421–3.PubMed

41.

Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503–12.PubMedPubMedCentral

42.

Zheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol. 2019;73(17):2150–62.PubMedPubMedCentral

43.

Banerjee D, Wong EC, Shin J, Fortmann SP, Palaniappan L. Racial and ethnic variation in lipoprotein(a) levels among Asian Indian and Chinese Patients. J Lipids. 2011;2011:291954.PubMedPubMedCentral

44.

Enkhmaa B, Anuurad E, Berglund L. Lipoprotein(a): impact by ethnicity and environmental and medical conditions. J Lipid Res. 2016;57(7):1111–25.PubMedPubMedCentral

45.

Parra HJ, Luyéyé I, Bouramoué C, Demarquilly C, Fruchart JC. Black-white differences in serum Lp(a) lipoprotein levels. Clin Chim Acta. 1987;168(1):27–31.PubMed

46.

Guyton JR, Dahlen GH, Patsch W, Kautz JA, A M Gotto J. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. Arteriosclerosis: An Official Journal of the American Heart Association, Inc [Internet]. 1985 Jun [cited 2020 Feb 15]; https://www.ahajournals.org/doi/abs/10.1161/01.atv.5.3.265. Accessed 15 Feb 2020.

47.

Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844–53.PubMedPubMedCentral

48.

Knapp RG, Schreiner PJ, Sutherland SE, Keil JE, Gilbert GE, Klein RL, et al. Serum lipoprotein(a) levels in elderly black and white men in the Charleston Heart Study. Clin Genet. 1993;44(5):225–31.PubMed

49.

Srinivasan SR, Dahlen GH, Jarpa RA, Webber LS, Berenson GS. Racial (black-white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study. Circulation. 1991;84(1):160–7.PubMed

50.

Steffen BT, Thanassoulis G, Duprez D, Stein JH, Karger AB, Tattersall MC, et al. Race-Based Differences in lipoprotein(a)-associated risk of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2019;39(3):523–9.PubMedPubMedCentral

51.

Gaillard T, Osei K. Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes. BMJ Open Diabetes Res Care. 2016;4(1):e000246.PubMedPubMedCentral

52.

Helmhold M, Bigge J, Muche R, Mainoo J, Thiery J, Seidel D, et al. Contribution of the apo[a] phenotype to plasma Lp[a] concentrations shows considerable ethnic variation. J Lipid Res. 1991;32(12):1919–28.PubMed

53.

Marcovina SM, Albers JJ, Wijsman E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res. 1996;37(12):2569–85.PubMed

54.

Deo RC, Wilson JG, Xing C, Lawson K, Kao WHL, Reich D, et al. Single-nucleotide polymorphisms in LPA explain most of the ancestry-specific variation in Lp(a) levels in African Americans. PLoS One [Internet]. 2011 Jan 24 [cited 2020 Feb 15];6(1). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3025914/. Accessed 15 Feb 2020.

55.

Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations between lipoprotein(a) Levels and cardiovascular outcomes in African Americans and Caucasians: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125(2):241–9.PubMed

56.

Grundy SM, Stone NJ, Bailey AL, Craig B, Birtcher KK, Blumenthal RS, et al. (2018) AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed

57.

Cook NR, Mora S, Ridker PM. Lipoprotein(a) and cardiovascular risk prediction among women. J Am Coll Cardiol. 2018;72(3):287–96.PubMedPubMedCentral

58.

Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246–55.PubMed

59.

Scharnagl H, Stojakovic T, Dieplinger B, Dieplinger H, Erhart G, Kostner GM, et al. Comparison of lipoprotein(a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;1(289):206–13.

60.

Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, et al. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol. 2019;13(3):374–92.PubMed

61.

Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J [Internet]. [cited 2020 Feb 4]; Available from: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehz310/5492355. Accessed 4 Feb 2020.

62.

Thompson G, Parhofer KG. Current role of lipoprotein apheresis. Curr Atheroscler Rep [Internet]. 2019 [cited 2020 Apr 16];21(7). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491397/. Accessed 16 Apr 2020.

63.

Lui M, Garberich R, Strauss C, Davin T, Knickelbine T. Usefulness of lipid apheresis in the treatment of familial hypercholesterolemia. J Lipids [Internet]. 2014 [cited 2020 Apr 8];2014. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4217354/. Accessed 8 Apr 2020.

64.

Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, et al. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both? Atheroscler Suppl. 2017;1(30):44–9.

65.

The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12.

66.

Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, et al. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study. Circ Genom Precis Med. 2018;11(2):e001696.PubMedPubMedCentral

67.

AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–67.

68.

Anderson TJ, Boden WE, Desvigne-Nickens P, Fleg JL, Kashyap ML, McBride R, et al. Safety profile of extended-release niacin in the AIM-HIGH trial. N Engl J Med. 2014;371(3):288–90.PubMedPubMedCentral

69.

Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol. 2020;75(2):133–44.PubMed

70.

O’Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk: insights from the FOURIER trial. Circulation. 2019;139(12):1483–92.PubMed

71.

Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2015;35(3):689–99.PubMedPubMedCentral

72.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study| Elsevier Enhanced Reader [Internet]. [cited 2020 Mar 22]. https://reader.elsevier.com/reader/sd/pii/S0140673615612521?token=7F42DDEE825CFFF47784525B56C8D3D15F019936124FA0A2E1055BC650E91D805A71583F82498D3635D72B0F98860AB5. Accessed 20 Mar 2020.

Title: Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations
Authors: Keon Pearson
Fatima Rodriguez
Publication date: 01-12-2020
Publisher: Springer Healthcare
Keywords: Stroke
Arterial Diseases
Published in: Cardiology and Therapy / Issue 2/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI: https://doi.org/10.1007/s40119-020-00177-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Lipoprotein(a) and Cardiovascular Disease Prevention across Diverse Populations

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

A Qualitative Analysis of Patient-Related Factors Associated With Implantable Cardioverter Defibrillator Acceptance

Expansion of TAVR into Low-Risk Patients and Who to Consider for SAVR

Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study

Effectiveness of Trimetazidine in Patients with Stable Angina Pectoris of Various Durations: Results from ODA

In-Hospital Outcomes of Patients With Pulmonary Hypertension and Cirrhosis: A 6-Year Population Cohort Study of Over One Million Patients

The Effect of Low-Dose Ticagrelor on Platelet Function Profiles in Patients With Stable Coronary Artery Disease in Trinidad: The TWIST Pilot Study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page